Protara Therapeutics, Inc.
HealthcareNASDAQ:TARA · NASDAQ Global Market
+$0.25 today
Vol 0.52M · Avg 0.73M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-29.2%
avg -70.8%
ROIC
-32.3%
avg -69.5%
ROA
-27.4%
avg -63.1%
Analysis
ROA is currently the strongest return metric at -27.4% versus its period average of -63.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jesse Shefferman | Co-founder, Chief Executive Officer, President & Director | $1.08M | — | 54 | $1.02M | 2.65% |
Leonardo Viana Nicacio | Chief Medical Officer | $872,337.00 | — | 48 | $158,000.00 | 0.41% |
Jacqueline Zummo | Co-Founder, Chief R&D Officer | $789,445.00 | — | 45 | $94,827.00 | 0.25% |
Patrick Fabbio | Chief Financial Officer | $782,409.00 | — | 58 | $64,115.00 | 0.17% |
Mary J. Grendell | General Counsel & Corporate Secretary | — | — | — | — | — |
Carla Beckham | Lead Medical Director, Head of Clinical Development of TARA-002 in NMIBC & Board-Certified Urologist | — | — | — | — | — |
Neal D. Shore | Medical Director of START Carolinas/ Carolina Urologic Research Center | — | — | — | — | — |
Justine O'Malley | Senior Vice President of Investor Relations & Corporate Affairs | — | — | — | — | — |
Shane Williams | Chief People Officer | — | — | — | — | — |
Hannah Fry | Vice President, Principal Accounting Officer & Controller | — | — | 35 | $42,723.00 | 0.11% |
William Conkling | Chief Commercial Officer | — | — | 54 | $158,000.00 | 0.41% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
2
$124,989.08
Net Sentiment
$124,989.08
Net selling
Most Active
Zummo Jacqueline
2 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| Apr 8, 2026 | Zummo Jacqueline Direct | Sell | 1.1K | $5.40 | $6,123.60 | |
| Apr 1, 2026 | Zummo Jacqueline Direct | Sell | 22.6K | $5.26 | $118,865.48 |
Analysis
Insiders reported 0 buys worth $0.00 and 2 sells worth $124,989.08 over the last 12 months. That adds up to net selling of $124,989.08. Zummo Jacqueline was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
SELLAS Life Sciences Group, Inc.
NASDAQ:SLS
$1.12B
Genfit S.A.
GNFT
$445.68M
Prelude Therapeutics Incorporated
NASDAQ:PRLD
$352.45M
OmniAb, Inc.
NASDAQ:OABI
$270.34M
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
$245.51M
Codexis, Inc.
NASDAQ:CDXS
$218.15M
MediWound Ltd.
NASDAQ:MDWD
$154.46M
Invivyd, Inc.
NASDAQ:IVVD
$102.20M
Neonc Technologies Holdings, Inc.
NASDAQ:NTHI
$94.98M
Sangamo Therapeutics, Inc.
NASDAQ:SGMO
$64.96M
Who manages TARA?
Protara Therapeutics, Inc. (TARA) lists 11 active executives. The top listed executive is Jesse Shefferman, Co-founder, Chief Executive Officer, President & Director.
Are TARA insiders buying or selling?
Recent insider activity shows net buying of $11.32M.
Explore More
Continue the stock analysis
Jump to another research area for this company.